| Project/Area Number |
23592327
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
MIYAGI Toru 金沢大学, 医学系, 協力研究員 (60467107)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIZOMAMI Atsushi 金沢大学, 医学系, 准教授 (50248580)
KONAKA Hiroyuki 金沢大学, 附属病院, 講師 (40334768)
SHIGEHARA Kazuyoshi 金沢大学, 医学系, 協力研究員 (20595459)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | Noscapine / renal cell cancer / prostate cancer / flavonoids / docetaxel / ノスカピン / 前立腺癌 / パクリタキセル耐性 / 植物フラボノイド / ドセタキセル耐性 / 腎癌 |
|---|
| Research Abstract |
Noscapine is clinically available safe medicine, and antitumor action is found in MDR-overexpressing cancer. Because it was considered that MDR overexpression was involved in drug resistance of the renal carcinoma, we added Noscapine to renal carcinoma cells ACHN and confirmed antitumor effect in in vitro and in vivo. We confirmed antitumor effect in the prostate cancer cell line. Noscapine inhibited the proliferation of not only androgen-independent prostate caner cells DU145 but also DU145-TxR which is resistant for paclitaxel and docetaxel.DU145-TxR overexpressed MDR mRNA and p-glycoprotein that stimulate.
For the purpose of expecting a synergistic effect with noscapine and flavonoids in prostate cancer, we investigated the effect of flavonoids on the androgen responsiveness. After LNCaP cells were transfected with PSA promoter-driven Luciferase reporter, cells were treated with DHT with flavonoids. Then naringenin showed the strong suppression of androgen responsiveness.
|
